Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582214 | 0.78 | VRK1 (0.38) | VRK1GRM5PDGFRBPDGFRA | |
| SCHEMBL23348685 | 0.74 | GRM5 (0.36) | VRK1GRM5PDGFRBPDGFRA | |
| SCHEMBL2696723 | 0.74 | VRK1 (0.38) | VRK1GRIN2BGRIN1CYP11B2PDGFRB | |
| SCHEMBL781323 | 0.72 | — | — | |
| SCHEMBL29384015 | 0.72 | — | — | |
| SCHEMBL19665087 | 0.71 | CA12 (0.50) | MAP4K4 | |
| SCHEMBL380344 | 0.70 | MAP4K4 (0.47) | VRK1MAP4K4 | |
| SCHEMBL19665077 | 0.69 | CES2 (0.39) | MAP4K4 | |
| SCHEMBL17144949 | 0.69 | VRK1 (0.32) | VRK1CYP11B2 | |
| SCHEMBL8774747 | 0.69 | EGLN1 (0.42) | GRM5GRIN2BGRIN1CYP11B2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3170824-A1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | Amgen, Inc (US) | 2017-05-24 | — | — | EP | disclosed |
| CN-102007125-B | fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2016-05-25 | — | — | CN | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2231663-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | VRK1 3748/4885GRM5 1799/4885GRIN2B 2213/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | VRK1 3748/4885GRM5 1799/4885GRIN2B 2213/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | VRK1 3748/4885GRM5 1799/4885GRIN2B 2213/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | VRK1 3748/4885GRM5 1799/4885GRIN2B 2213/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | VRK1 3748/4885GRM5 1799/4885GRIN2B 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.